智通财经APP获悉，9月24日，全球临床试验收录网站显示，赛诺菲(SNY.US)的TSLP/IL-13双抗Lunsekimig(SAR443765)推进至II/III期阶段，针对慢性阻塞性肺病(COPD)启动了两项II/III期临床试验(THESEUS和PERSEPHONE)。
两项研究拟纳入1884例患者，旨在评估Lunsekimig(两个剂量，皮下注射)对比安慰剂治疗控制不佳的嗜酸性粒细胞表型COPD成人患者的有效性和安全性。研究的主要终点为基线至第48周中重度COPD恶化的年化发生率。
此前，赛诺菲曾公布Lunsekimig治疗哮喘的Ib期概念验证研究数据。数据显示，哮喘患者经400mg Lunsekimig治疗28天后，呼出一氧化碳分数(FENO)较基线显著降低，较安慰剂组降幅为40.9ppb(p<0.0001)。此外，患者的2型炎症反应生物标志物水平亦显著降低。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.